Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease, is a progressive neurodegenerative disease. It is characterized by the destruction of motor neurons or nerve cells that control muscle movement, leading to disability. Incidence of ALS The average incidence rate of ALS worldwide is about one in…
In contrast to what is often assumed, new research suggests that clumps of the protein TDP-43 — a hallmark of amyotrophic lateral sclerosis (ALS) — actually protect nerve cells rather than harm them. If this finding confirmed in future studies, it could hugely impact how ALS and other neurodegenerative diseases…
The release of fragmented or dysfunctional mitochondria — a cell’s powerhouse — by immune and structural cells inside the central nervous system is a critical step that triggers neuron death and the progression of human neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS), a study shows.
What is ALS? Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease, is a progressive neurological disorder that affects the nerves that control muscle movement. Patients are generally diagnosed between ages 55–75. Symptoms can range from mild to very severe and may progress at different rates for different…
After gathering input from patients, researchers, and advocates, the U.S Food and Drug Administration (FDA) has released new guidance on the development of therapies for amyotrophic lateral sclerosis (ALS). Among its recommendations, it is advising more communication with companies early on in the product development process, access to…
A detailed analysis of the communication network between nerve and muscle cells in turtles has shed new light on how movement is controlled and maintained. These findings on how motor nerve cells communicate may help scientists better understand the underlying mechanisms of amyotrophic lateral sclerosis (ALS) or spinal injury.
Kadimastem’s experimental cell therapy — AstroRx — may slow disease progression in patients with amyotrophic lateral sclerosis (ALS), according to interim results in a first group of patients treated in a Phase 1/2a study. AstroRx consists of functional healthy astrocytes — cells that support and protect neurons…
The Sean M. Healey & AMG Center at Mass General has chosen five “promising” candidate treatments from among 30 applications to test in its first platform trial for amyotrophic lateral sclerosis (ALS). The platform trial — a type of a clinical study that tests the efficacy of multiple…
A toxin produced by algae may contribute to the development of amyotrophic lateral sclerosis (ALS) by lowering the stability of a protein in the brain, a new study suggests. Titled “β-Methylamino-L-alanine substitution of serine in SOD1 suggests a direct role in ALS etiology,” the study was…
Fight Motor Neuron Disease (FightMND) has awarded Clene Nanomedicine‘s Australian subsidiary $1.37 million AUD (approximately $924,000) to advance clinical studies of a new amyotrophic lateral sclerosis (ALS) candidate treatment. These funds will support a Phase 2 clinical trial, named RESCUE-ALS, that will assess the efficacy and safety…
